Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast CancerNicholas C. Turner, Komal Jhaveri, Seock‐Ah Im et al.|New England Journal of Medicine|2024Cited by 235
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancerMaria Vittoria Dieci, Valentina Guarneri, PierFranco Conte et al.|Annals of Oncology|2019Cited by 96
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, PierFranco Conte, Maria Vittoria Dieci et al.|European Journal of Cancer|2021Cited by 42
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Valentina Guarneri, Federico Piacentini et al.|Journal of Clinical Oncology|2023Cited by 25